Brief: Cosmo Pharmaceuticals H1 Operating Income EUR -1.411 Million
23/07/2025 06:09
Jul 23 (Reuters) - Cosmo Pharmaceuticals H1 revenue EUR 51.72 million. H1 gross profit EUR 26.149 million H1 operating expenses EUR -27.56 million H1 EBITDA EUR 4.852 million H1 EPS EUR -0.126
Recent news on Cosmo NV
See all newsFocus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance
Brief: Cosmo Pharmaceuticals H1 EPS EUR -0.279
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
Europe Research Roundup: Airbus ,Bechtle, Salzgitter